olcegepant

Olcegepant is a potent and selective small molecule antagonist of the calcitonin gene-related peptide (CGRP) receptor. Developed by Boehringer Ingelheim Pharmaceuticals, it was investigated primarily for the acute treatment of migraine attacks. Olcegepant works by blocking CGRP receptors, thereby inhibiting the action of CGRP—a neuropeptide implicated in migraine pathophysiology through its role in mediating neurogenic inflammation and vasodilation within cerebral vessels. Unlike triptans and dihydroergotamine, olcegepant does not cause vasoconstriction, making it potentially suitable for patients with cardiovascular risk factors. Clinical trials demonstrated efficacy in reducing headache severity and associated symptoms; however, development was ultimately terminated after phase II trials[1][2][3][5].

Other names

olcegepant